Novo Nordisk Adr (NVO)

12:30 PM

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? - The Motley Fool

12:30 PM

Feb 23, 2026

Novo Nordisk Is Losing Share, but We Still See Its Portfolio and Pipeline Supporting a Wide Moat - Morningstar

Feb 23, 2026

Feb 23, 2026

Stock Of The Day: Breakdown In Novo Nordisk? - Finviz

Feb 23, 2026

Feb 23, 2026

Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal agains - The Economic Times

Feb 23, 2026

Feb 23, 2026

Pre-market Overview | Uncertainty looms over US tariff policy! All three major futures indices trend lower; popular Chinese ADRs active in pre-market trading, with PDD Holdings up over 3%; Novo-Nordisk A/S plunges 14% as its next-generation weight-loss dr - 富途牛牛

Feb 23, 2026

Feb 23, 2026

Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial - CNBC

Feb 23, 2026

Feb 20, 2026

Does Novo Nordisk A s (b Shares) Adrhedged stock benefit from AI growthQuarterly Profit Review & AI Powered Buy/Sell Recommendations - mfd.ru

Feb 20, 2026

Feb 20, 2026

Novo Nordisk stock forecast: Analysts mixed on Q4 earnings & 2026 guidance - Capital.com

Feb 20, 2026

Feb 20, 2026

Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.

Feb 20, 2026

Feb 18, 2026

EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients - Finviz

Feb 18, 2026

Feb 18, 2026

Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.

Feb 18, 2026

Feb 14, 2026

Novo Nordisk Balances Oral Wegovy Launch With Legal Fight On Compounds - Sahm

Feb 14, 2026

Feb 13, 2026

Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm

Feb 13, 2026

Feb 13, 2026

FDA Crackdown Reshapes Wegovy Competition And Risks For Novo Nordisk Investors - Sahm

Feb 13, 2026

Feb 11, 2026

Can Novo Nordisk A s (b Shares) Adrhedged outperform in the next rallyIPO Watch & Safe Capital Growth Stock Tips - mfd.ru

Feb 11, 2026

Feb 10, 2026

Where is Novo Nordisk A/S (NVO) Headed? - Finviz

Feb 10, 2026

Feb 09, 2026

Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm

Feb 09, 2026

Feb 08, 2026

Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz

Feb 08, 2026

Feb 07, 2026

Jim Cramer on Novo Nordisk: "It Seems Eli Lilly's Eating Their Lunch" - Finviz

Feb 07, 2026

Feb 06, 2026

Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify - Sahm

Feb 06, 2026

Feb 05, 2026

Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm

Feb 05, 2026

Feb 04, 2026

Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - Morningstar

Feb 04, 2026

Feb 04, 2026

Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? - Finviz

Feb 04, 2026

Feb 04, 2026

NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz

Feb 04, 2026